Drugs / Algenpantucel-L
Algenpantucel-L
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00255827 | Nov 2005 → Sep 2007 | malignant pancreatic neoplasm | NewLink Genetics Corporation | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT02405585 | Apr 2015 → Jun 2016 | exocrine pancreatic carcinoma | NewLink Genetics Corporation | Terminated | No outcome recorded |
| Phase 2 | NCT00614601 | Jan 2008 → May 2010 | malignant pancreatic neoplasm | NewLink Genetics Corporation | Terminated | No outcome recorded |
| Phase 2 | NCT00569387 | Dec 2007 → Mar 2011 | malignant pancreatic neoplasm | NewLink Genetics Corporation | Completed | No outcome recorded |
| Phase 32 trials · 1 missed | ||||||
| Phase 3 | NCT01836432 | May 2013 → Jul 2016 | pancreatic ductal adenocarcinoma | NewLink Genetics Corporation | Terminated | Missed primary |
| Phase 3 | NCT01072981 | Apr 2010 → May 2016 | malignant pancreatic neoplasm | NewLink Genetics Corporation | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Algenpantucel-L | “A Phase I/II Study of Algenpantucel-L (HyperAcute Pancreas) an Antitumor Vaccination Using Alpha(1,3)Galactosyltransferase Expressing Allogeneic Tumor Cells in Patients With...” NCT00255827 ↗5“A Phase II Study of Low Dose Algenpantucel-L (HyperAcute Pancreas) Cancer Vaccine in Subjects With Surgically Resected Pancreatic Cancer” NCT00614601 ↗ “A Phase II Study of Algenpantucel-L (HyperAcute Pancreas) Cancer Vaccine in Subjects With Surgically Resected Pancreatic Cancer” NCT00569387 ↗ “algenpantucel-L (NewLink Genetics Corporation, Ames, IA) immunotherapy” PMID 23229886 ↗ Nov 2012 |
| Known as | HAPA | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108717 ↗ |
| Known as | HyperAcute-Pancreas | “A Phase III Study of Chemotherapy and Chemoradiotherapy With or Without Algenpantucel-L (HyperAcute®-Pancreas) Immunotherapy in Subjects With Surgically Resected Pancreatic Cancer” NCT01072981 ↗1“Algenpantucel-L (HyperAcute Pancreas) an Antitumor Vaccination” NCT00255827 ↗ |
| Known as | HyperAcute-Pancreas Immunotherapy | “A Phase III Study of Chemotherapy and Chemoradiotherapy With or Without Algenpantucel-L (HyperAcute®-Pancreas) Immunotherapy in Subjects With Surgically Resected Pancreatic Cancer” NCT01072981 ↗ |
| Modality | Vaccine | “genetically engineered HyperAcute-Pancreatic cancer vaccine” NCT00255827 ↗ |
| Route | Other | “injected intradermally” NCT00614601 ↗ |